Aveanna Healthcare Reports Strong Q4 2025 Earnings with Strategic Growth Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy AVAH?
Source: seekingalpha
- Significant Revenue Growth: Aveanna Healthcare reported approximately $662.5 million in Q4 2025 revenue, marking a 27.4% year-over-year increase, with full-year revenue reaching about $2.433 billion, showcasing the company's strong growth potential under its preferred payer strategy.
- Outstanding EBITDA Performance: The adjusted EBITDA for Q4 was $85 million, up 54% year-over-year, reflecting the company's success in operational efficiency and cost control, with expectations for 2026 EBITDA to remain between $318 million and $322 million.
- Acquisition Plans Advancing: The company announced the acquisition of Family First Homecare, expected to close in Q2 2026, which is anticipated to enhance its market presence in Florida, alongside plans to add eight new preferred payer agreements in 2026, targeting a total of 38 by year-end.
- Optimistic Future Outlook: Management projects 2026 revenue in the range of $2.54 billion to $2.56 billion, emphasizing a continued focus on technology investments and operational efficiency to support future growth strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVAH
Wall Street analysts forecast AVAH stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 6.340
Low
10.00
Averages
10.75
High
11.00
Current: 6.340
Low
10.00
Averages
10.75
High
11.00
About AVAH
Aveanna Healthcare Holdings Inc. is a provider of diversified home care platforms. Its segments include Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS segment includes private duty nursing (PDN) services, as well as pediatric therapy services. HHH segment includes home health services, as well as hospice and specialty program services. Its home health services involve the provision of in-home services to its patients by its clinicians, which include nurses, therapists, social workers and home health aides. Its hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Medical Solutions segment offers a line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. It also provides case management services to assist families and patients by coordinating the provision of services between insurers and other healthcare providers.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

- Significant Revenue Growth: Aveanna Healthcare reported approximately $662.5 million in Q4 2025 revenue, marking a 27.4% year-over-year increase, with full-year revenue reaching about $2.433 billion, showcasing the company's strong growth potential under its preferred payer strategy.
- Outstanding EBITDA Performance: The adjusted EBITDA for Q4 was $85 million, up 54% year-over-year, reflecting the company's success in operational efficiency and cost control, with expectations for 2026 EBITDA to remain between $318 million and $322 million.
- Acquisition Plans Advancing: The company announced the acquisition of Family First Homecare, expected to close in Q2 2026, which is anticipated to enhance its market presence in Florida, alongside plans to add eight new preferred payer agreements in 2026, targeting a total of 38 by year-end.
- Optimistic Future Outlook: Management projects 2026 revenue in the range of $2.54 billion to $2.56 billion, emphasizing a continued focus on technology investments and operational efficiency to support future growth strategies.
See More
- Significant Stock Drop: Aveanna Healthcare (AVAH) shares fell approximately 10% on Thursday, marking its largest intraday decline in over a year, primarily due to its 2026 revenue outlook missing the midpoint of market consensus.
- Revenue Guidance Maintained: Although the company maintained its 2026 revenue guidance between $2.54 billion and $2.56 billion, this forecast falls short of analysts' expectations of $2.56 billion, reflecting market concerns about future growth.
- Earnings Beat Expectations: Aveanna's Q4 2025 revenue grew approximately 27% year-over-year to $662.5 million, driving full-year revenue up about 20% to $2.4 billion, indicating strong performance in the market.
- Adjusted EBITDA Surge: The adjusted EBITDA for Q4 increased roughly 54% year-over-year to $85 million, exceeding the consensus estimate of $78.8 million, while the full-year adjusted EBITDA jumped about 75% to $320.9 million, showcasing a significant improvement in the company's profitability.
See More

- Strong Earnings Report: Aveanna Healthcare Holdings reported a Q4 GAAP EPS of $0.80, beating estimates by $0.65, which highlights the company's significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $662.5 million, representing a 27.4% year-over-year increase, surpassing market expectations by $13.02 million, indicating robust demand in the healthcare services sector.
- 2026 Financial Guidance: Aveanna maintains its 2026 revenue guidance between $2.54 billion and $2.56 billion, aligning with the market consensus of $2.56 billion, demonstrating confidence in future growth prospects.
- Adjusted EBITDA Outlook: The company also keeps its 2026 adjusted EBITDA guidance in the range of $318 million to $322 million, reflecting ongoing efforts in cost control and operational efficiency.
See More
- Earnings Announcement: Aveanna Healthcare Holdings (AVAH) is set to announce its Q4 earnings on March 19 before market open, with consensus EPS estimate at $0.16, reflecting a substantial 220% year-over-year increase, and revenue expected at $649.48 million, up 24.9% year-over-year.
- Consistent Outperformance: Over the past year, Aveanna has consistently beaten EPS and revenue estimates, demonstrating strong profitability and market adaptability, which enhances investor confidence in the stock.
- Revisions Trend: In the last three months, EPS estimates have seen seven upward revisions with no downward adjustments, while revenue estimates experienced six upward revisions and one downward, indicating analysts' optimistic outlook on the company's future performance.
- Acquisition Strategy: Aveanna plans to acquire Family First Homecare for $176 million, a move that will not only expand its market share but also strengthen its competitive position in the home healthcare sector, further driving company growth.
See More
- Acquisition Agreement: Aveanna Healthcare announced an agreement to acquire Family First Homecare for $175.5 million, aiming to expand its geographic footprint in specialized care, with the transaction expected to close in Q2 2026.
- Diverse Funding Sources: The acquisition will be funded through a combination of cash on hand and debt, demonstrating the company's flexibility in capital management and confidence in future growth.
- Clear Market Positioning: Family First Homecare operates 27 locations across seven states, including Florida, focusing on private duty nursing services for the pediatric population, aligning with Aveanna's strategic mission to deliver high-quality care.
- High Cultural Fit: Aveanna CEO Jeff Shaner emphasized that Family First Homecare is a tremendous cultural fit, which is expected to bring unprecedented value and clinical innovation to payors and stakeholders.
See More
- Earnings Release Schedule: Aveanna Healthcare is set to announce its fourth quarter and full year results on March 19, 2026, before market open, which is expected to provide investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: The company will host a conference call at 10:00 a.m. (Eastern Time) on the same day, allowing investors to participate by dialing 1-877-407-0789, with international callers using 1-201-689-8562, ensuring global investor engagement in the discussion.
- Replay Service: A replay of the conference call will be available three hours after its conclusion, accessible by dialing 1-844-512-2921 (international callers can use 1-412-317-6671), with the replay service lasting until March 26, 2026, facilitating information access for those unable to attend live.
- Online Webcast: Investors can also listen to a simultaneous webcast of the conference call via the Investor Relations section of the company's website, with the online replay available for one week post-call, further enhancing information accessibility and transparency.
See More








